Star Scientific (STSI) Star Scientific engages in the manufacture, distribution, and sale of consumer products, dietary supplements, and dissolvable tobacco. They also have several products which have a botanical-based component designed to treat a range of neurological conditions including Alzheimer’s…
Author: Scott Matusow
Sunday Night Biotech Commentary: $ALXA, $STSI
Some Sunday night biotech commentary, mainly on Jason Napadano’s reference to me on Seeking Alpha (HERE) concerning Alexza (ALXA). I also mention Star Sciences (STSI) as well.
My video commentary on The Negative Article about Alexza 12/5/12, written by Jason Napodano
My video commentary on The Negative Article about Alexza 12/5/12, written by Jason Napodano, CFA which can be found at http://propthink.com/alexza-meaningfully-overvalued-following-its-latest-rally/4120
Voce Capital Management Goes Hardball With Proxy Fight Against Obagi Board
Another chapter has been written on the nearly year long effort by Voce Capital management to get Obagi Medical Products (OMPI) sold, when on Monday, 12/3/12, Voce made public another letter sent to the Obagi Board of Directors (BOD) In…
XenoPort Catalyst DD – December 31st
Catalyst: XenoPort conducted an End-of-Phase 2 meeting with the FDA in which it received feedback that a proposed development program for XP21279, a novel prodrug of levodopa, could support a potential New Drug Application (NDA) submission under Section 505(b)(2) of…
3 Small Cap Bio-Pharmas With Trade Catalysts And Speculation Investment Potential
Zogenix (ZGNX) engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. Its commercial product includes Sumavel DosePro (sumatriptan injection), a delivery system that offers needle-free subcutaneous administration of sumatriptan for the…
MEI Pharma (MEIP): Significant Catalyst Trade Potential
MEI Pharma, Inc. (MEIP), will be presenting data on Pracinostat, in combination with azacitidine in patients with advanced myelodysplastic syndrome (MDS) at a poster presentation at the American Society of Hematology Annual Meeting on December 10, 2012. An abstract of…
11/30/12 Catalyst Trade And Speculation Investment List
Alexza Pharma (NASDAQ: ALXA) Alexza engages in the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions worldwide. Its product candidates are based on a proprietary technology, the Staccato system, which vaporizes…
Theravance (THRX) reports outcome of the FDA Advisory Committee
Theravance (THRX) reports outcome of the FDA Advisory Committee meeting on VIBATIV (telavancin) for the treatment of nosocomial pneumonia (stock halted) (THRX) 21.40 +0.00 : Co announced the outcome of the Anti-Infective Drugs Advisory Committee (AIDAC) of the FDA meeting…
Huge Swing Trade Potential For Alexza Pharma With Two December Catalysts
Alexza Pharma (NASDAQ: ALXA) engages in the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. Its product candidates are based on a proprietary technology, the Staccato system, which vaporizes an excipient-free…
